BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

507 related articles for article (PubMed ID: 34481658)

  • 21. Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
    Popat R; Brown SR; Flanagan L; Hall A; Gregory W; Kishore B; Streetly M; Oakervee H; Yong K; Cook G; Low E; Cavenagh J;
    Lancet Haematol; 2016 Dec; 3(12):e572-e580. PubMed ID: 27843120
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sequential bortezomib, dexamethasone, and thalidomide maintenance therapy after single autologous peripheral stem cell transplantation in patients with multiple myeloma.
    Sahebi F; Frankel PH; Farol L; Krishnan AY; Cai JL; Somlo G; Thomas SH; Reburiano E; Popplewell LL; Parker PM; Spielberger RT; Kogut NM; Karanes C; Htut M; Ruel C; Duarte L; Murata-Collins JL; Forman SJ
    Biol Blood Marrow Transplant; 2012 Mar; 18(3):486-92. PubMed ID: 22198542
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study.
    Zervas K; Dimopoulos MA; Hatzicharissi E; Anagnostopoulos A; Papaioannou M; Mitsouli Ch; Panagiotidis P; Korantzis J; Tzilianos M; Maniatis A;
    Ann Oncol; 2004 Jan; 15(1):134-8. PubMed ID: 14679133
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lenalidomide: A Review in Newly Diagnosed Multiple Myeloma as Maintenance Therapy After ASCT.
    Syed YY
    Drugs; 2017 Sep; 77(13):1473-1480. PubMed ID: 28791622
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Results from Two Consecutive Studies of Consolidation Therapy after Autologous Transplant for Multiple Myeloma: Thalidomide, Dexamethasone, and Clarithromycin or Lenalidomide, Dexamethasone, and Clarithromycin.
    Holmberg LA; Becker PS; Bensinger W
    Acta Haematol; 2017; 137(3):123-131. PubMed ID: 28355602
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma.
    Cavo M; Pantani L; Petrucci MT; Patriarca F; Zamagni E; Donnarumma D; Crippa C; Boccadoro M; Perrone G; Falcone A; Nozzoli C; Zambello R; Masini L; Furlan A; Brioli A; Derudas D; Ballanti S; Dessanti ML; De Stefano V; Carella AM; Marcatti M; Nozza A; Ferrara F; Callea V; Califano C; Pezzi A; Baraldi A; Grasso M; Musto P; Palumbo A;
    Blood; 2012 Jul; 120(1):9-19. PubMed ID: 22498745
    [TBL] [Abstract][Full Text] [Related]  

  • 27. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma.
    Cavo M; Zamagni E; Tosi P; Cellini C; Cangini D; Tacchetti P; Testoni N; Tonelli M; de Vivo A; Palareti G; Tura S; Baccarani M
    Haematologica; 2004 Jul; 89(7):826-31. PubMed ID: 15257934
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Thalidomide treatment for patients with previously untreated multiple myeloma: a meta-analysis of randomized controlled trials.
    Gao M; Kong Y; Wang H; Xie B; Yang G; Gao L; Zhang Y; Zhan F; Dai B; Tao Y; Shi J
    Tumour Biol; 2016 Aug; 37(8):11081-98. PubMed ID: 26906553
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients.
    Palumbo A; Gay F; Falco P; Crippa C; Montefusco V; Patriarca F; Rossini F; Caltagirone S; Benevolo G; Pescosta N; Guglielmelli T; Bringhen S; Offidani M; Giuliani N; Petrucci MT; Musto P; Liberati AM; Rossi G; Corradini P; Boccadoro M
    J Clin Oncol; 2010 Feb; 28(5):800-7. PubMed ID: 20048187
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The clinical impact of thalidomide maintenance after autologous stem cell transplantation in patients with newly diagnosed multiple myeloma in real clinical practice of Korea.
    Lee HS; Min CK; Lee JJ; Kim K; Kim SJ; Yoon DH; Eom HS; Lee H; Lee WS; Shin HJ; Lee JH; Park Y; Jo JC; Do YR; Mun YC; Lee MH;
    Ann Hematol; 2016 May; 95(6):911-9. PubMed ID: 27052989
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thalidomide, cyclophosphamide and dexamethasone induction therapy: feasibility for myeloma patients destined for autologous stem cell transplantation.
    Chang WJ; Kang ES; Lee ST; Kim SH; Kim DW; Kim SJ; Kim K
    Acta Haematol; 2014; 132(2):226-32. PubMed ID: 24732093
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sequential treatment with bortezomib plus dexamethasone followed by autologous hematopoietic stem cell transplantation in patients with multiple myeloma.
    Zheng D; Li J; Huang BH; Liu JR; Zou WY; Su C
    Chin Med J (Engl); 2012 Dec; 125(24):4454-9. PubMed ID: 23253719
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial.
    Manasanch EE; Shah JJ; Lee HC; Weber DM; Thomas SK; Amini B; Feng L; Berkova Z; Hildebrandt M; Orlowski RZ
    Lancet Haematol; 2018 Dec; 5(12):e628-e640. PubMed ID: 30501870
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thalidomide plus dexamethasone as a maintenance therapy after autologous hematopoietic stem cell transplantation improves progression-free survival in multiple myeloma.
    Maiolino A; Hungria VT; Garnica M; Oliveira-Duarte G; Oliveira LC; Mercante DR; Miranda EC; Quero AA; Peres AL; Barros JC; Tanaka P; Magalhães RP; Rego EM; Lorand-Metze I; Lima CS; Renault IZ; Braggio E; Chiattone C; Nucci M; de Souza CA;
    Am J Hematol; 2012 Oct; 87(10):948-52. PubMed ID: 22730113
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Autologous-allogeneic
    Kröger N; Wulf G; Hegenbart U; Burchert A; Stelljes M; Gagelmann N; Brecht A; Kaufmann M; Müller L; Ganser A; Wolf D; Bethge W; Bornhäuser M; Kiehl M; Wagner EM; Schmid C; Reinhardt HC; Kobbe G; Salwender H; Heinicke T; Kropff M; Heinzelmann M; Ayuk F; Trümper L; Neubauer A; Völp A; Kluychnikov E; Schönland S; Wolschke C
    Haematologica; 2024 May; 109(5):1469-1479. PubMed ID: 37941409
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Advances in maintenance strategy in newly diagnosed multiple myeloma patients eligible for autologous transplantation.
    Wahab A; Rafae A; Faisal MS; Mushtaq K; Ehsan H; Khakwani M; Ashraf A; Rehan T; Ahmed Z; Shah Z; Khan A; Anwer F
    Expert Rev Hematol; 2020 Dec; 13(12):1333-1347. PubMed ID: 33078986
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Bortezomib-based induction therapy followed by autologous hematopoietic stem cell transplantation in multiple myeloma].
    Huang B; Li J; Liu J; Gu J; Zheng D; Xu D; Zou W; Wang H
    Zhonghua Nei Ke Za Zhi; 2014 Nov; 53(11):865-72. PubMed ID: 25586356
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study.
    Rosiñol L; Oriol A; Teruel AI; Hernández D; López-Jiménez J; de la Rubia J; Granell M; Besalduch J; Palomera L; González Y; Etxebeste MA; Díaz-Mediavilla J; Hernández MT; de Arriba F; Gutiérrez NC; Martín-Ramos ML; Cibeira MT; Mateos MV; Martínez J; Alegre A; Lahuerta JJ; San Miguel J; Bladé J;
    Blood; 2012 Aug; 120(8):1589-96. PubMed ID: 22791289
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and Safety of a Weekly Cyclophosphamide-Bortezomib-Dexamethasone Regimen as Induction Therapy Prior to Autologous Stem Cell Transplantation in Japanese Patients with Newly Diagnosed Multiple Myeloma: A Phase 2 Multicenter Trial.
    Tanaka K; Toyota S; Akiyama M; Wakimoto N; Nakamura Y; Najima Y; Doki N; Kakihana K; Igarashi A; Kobayashi T; Ohashi K; Kudo D; Shinagawa A; Takano H; Fujio T; Okoshi Y; Hori M; Kumagai T; Saito T; Mukae J; Yamamoto K; Tsutsumi I; Komeno T; Yoshida C; Yamamoto M; Kojima H;
    Acta Haematol; 2019; 141(2):111-118. PubMed ID: 30726834
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma.
    Mark TM; Bowman IA; Rossi AC; Shah M; Rodriguez M; Quinn R; Pearse RN; Zafar F; Pekle K; Jayabalan D; Ely S; Coleman M; Chen-Kiang S; Niesvizky R
    Leuk Lymphoma; 2014 Dec; 55(12):2842-9. PubMed ID: 24576165
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.